Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lepu Scientech Medical Technology (Shanghai) Co Buyback Yield % Chart
Lepu Scientech Medical Technology (Shanghai) Co Annual Data
HKSE:02291 vs ABT, SYK, MDT: Buyback Yield % Comparison
For the Medical Devices subindustry, Lepu Scientech Medical Technology (Shanghai) Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lepu Scientech Medical Technology (Shanghai) Co Buyback Yield % vs Medical Devices & Instruments Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291) has a Buyback Yield % of 0.00 as of Sep. 12, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Lepu Scientech Medical Technology (Shanghai) Co and its competitors. According to the industry distribution chart, Lepu Scientech Medical Technology (Shanghai) Co ranks #999999 out of 328 companies in the Medical Devices & Instruments industry.
Is Lepu Scientech Medical Technology (Shanghai) Co's Buyback Yield % too high?
Lepu Scientech Medical Technology (Shanghai) Co's current Buyback Yield % is 0.00. Based on the distribution chart, Lepu Scientech Medical Technology (Shanghai) Co ranks #999999 out of 328 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Lepu Scientech Medical Technology (Shanghai) Co has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lepu Scientech Medical Technology (Shanghai) Co's Buyback Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Lepu Scientech Medical Technology (Shanghai) Co ranks #999999 out of 328 companies for Buyback Yield %. This places Lepu Scientech Medical Technology (Shanghai) Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Lepu Scientech Medical Technology (Shanghai) Co and its competitors. Lepu Scientech Medical Technology (Shanghai) Co's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lepu Scientech Medical Technology (Shanghai) Co stock overvalued right now?
Based on GuruFocus' analysis, Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$45.87, compared to a current price of HK$10.49 — trading 77.1% below its estimated fair value. The current Buyback Yield % is 0.00. Lepu Scientech Medical Technology (Shanghai) Co's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291), the current Buyback Yield % is 0.00 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291) Overvalued in 2026?
Based on GuruFocus' analysis, Lepu Scientech Medical Technology (Shanghai) Co stock appears to be undervalued.
The current stock price of HK$10.49 is trading 77.1% below its estimated GF Value™ of HK$45.87.
GuruFocus considers Lepu Scientech Medical Technology (Shanghai) Co to be Significantly Undervalued.
Key valuation signals for HKSE:02291:
Buyback Yield %: 0.00
GF Value™: HK$45.87 vs. price of HK$10.49 (77.1% below fair value)
No single metric tells the full story. See the HKSE:02291 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lepu Scientech Medical Technology (Shanghai) Co Ltd is focused on the research and development, manufacture, and commercialization of heart disease interventional medical devices. The reporting segments of the Group are as follows: The Occluder business segment and The heart valve business segment. The company generates majority of its revenue from the Occluder segment which is engaged in the research and development, manufacturing and sales of interventional treatment series occluders for the defective congenital heart disease.
82GF Score
Get the complete analysis for HKSE:02291
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02291 has been successfully added to your 
